A randomized phase III clinical trial on the effect of MV130 in the prevention of wheezing attacks in children under 3 years of age has been published in the American Journal of Respiratory and Critical Care Medicine.   

The trial, double-blind, placebo-controlled, performed on a cohort of 120 children, was aimed primarily at evaluating the safety and efficacy of MV130. The results indicate a very significant reduction in the number and duration of wheezing attacks with a high level of safety.

MV130 (Bactek^®) is a polybacterial preparation for sublingual administration in spray composed of fully inactivated whole bacteria. MV130 acts as a non-specific immunotherapy against different pathogens including respiratory viruses,  the main cause of wheezing attacks in young children. MV130 has the features of trained immunity-based vaccines (TIbV), which are conceptually novel vaccines that confer long-lasting  non-specific protection while promoting adaptive responses against eventual concurrent infections.

The study was conducted in several hospitals in Spain (Comunidad Valenciana)  under the direction of Dr. Antonio Nieto, Hospital Universitario La Fe, Valencia, in collaboration and sponsorship of INMUNOTEK.